A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
Biliary Tract Cancer
OTHER: No Intervention
Number of Participants With Adverse Drug Reactions, Up to 1 year
Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment, Up to 1 year
The primary purpose of this study is to investigate the safety of Tasfygo.